International variation in prescribing antihypertensive drugs: Its extent and possible explanations

BMC Health Services Research

Volumn 5, Issue , 2005, Pages

  Fretheim, Atle ^a   Oxman, Andrew D ^a  

^a Norwegian Health Services Research Centre   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

ARTICLE; CLINICAL PRACTICE; DRUG CONTROL; DRUG COST; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; DRUG UTILIZATION; FRANCE; GERMANY; HUMAN; HYPERTENSION; INTERVIEW; NORWAY; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; QUESTIONNAIRE; REIMBURSEMENT; UNITED KINGDOM; UNITED STATES; AWARENESS; CANADA; CLASSIFICATION; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; ECONOMICS; EUROPE; HEALTH PERSONNEL ATTITUDE; HEALTH SERVICE; STATISTICS AND NUMERICAL DATA;

ANTIHYPERTENSIVE AGENTS; ATTITUDE OF HEALTH PERSONNEL; AWARENESS; CANADA; CLINICAL TRIALS AS TOPIC; DRUG COSTS; DRUG INDUSTRY; DRUG PRESCRIPTIONS; DRUG UTILIZATION; EUROPE; HEALTH SERVICES MISUSE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; UNITED STATES;

EID: 18944381554     PISSN: 14726963     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-5-21     Document Type: Article

References (18)

1. References 1. Fretheim A, Aaserud M, Oxman AD: The potential savings of using thiazides as the first choice antihypertensive drug: cost-minimisation analysis. BMC Health Serv Res 2003, 3:18.
2. WHO Collaborating Centre for Drug Statistics Methodology: ATC index with DDDs 2000 Oslo, WHO Collaborating Centre for Drug Statistics Methodology; 2000.
3. Drug Consumption in Norway 1999-2003. Edited by: Rønning M. Oslo, Norwegian Institute of Public Health; 2004.
4. Nielsen A: Medicines consumption in the Nordic countries Edited by: Nielsen J. Copenhagen, Nordisk Medicinalstatistisk Komité; 2001:171-256.
5. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000, 283:1967-1975.
6. Stafford RS, Furberg CD, Finkelstein SN, Cockburn IM, Alehegn T, Ma J: Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002. JAMA 2004, 291:54-62.
7. Felleskatalogen AS: Felleskatalogen 43rd edition. Oslo, Felleskatalogen AS; 2001.
8. Waaler HT, Hjort PF: The consumption of blood pressure lowering drugs in the Nordic countries. In Nordic statistics on Medicines Uppsala/Oslo, The Nordic Council on Medicines; 1983:195-215.
9. Goodman B: Do drug company promotions influence physician behavior? West J Med 2001, 174:232-233.
10. Grimshaw JM, Shirran L, Thomas R, Mowatt G, Fraser C, Bero L, Grilli R, Harvey E, Oxman A, O'Brien MA: Changing provider behavior: an overview of systematic reviews of interventions. Med Care 2001, 39:II2-45.
11. Gosden T, Torgerson DJ: The effect of fundholding on prescribing and referral costs: a review of the evidence. Health Policy 1997, 40:103-114.
12. Jacoby A, Smith M, Eccles M: A qualitative study to explore influences on general practitioners' decisions to prescribe new drugs. Br J Gen Pract 2003, 53:120-125.
13. Walley T, Folino-Gallo P, Schwabe U, van Ganse E: Variations and increase in use of statins across Europe: data from administrative databases. BMJ 2004, 328:385-386.
14. Pena E: The Value of Phase IV. PharmaVoice 2003:8-18.
15. Kessler DA, Rose JL, Temple RJ, Schapiro R, Griffin JP: Therapeutic-class wars - drug promotion in a competitive marketplace. N Engl J Med 1994, 331:1350-1353.
16. Stephens MD: Marketing aspects of company-sponsored postmarketing surveillance studies. Drug Saf 1993, 8:1-8.
17. Maclure M, Dormuth C, Naumann T, McCormack J, Rangno R, Whiteside C, Wright JM: Influences of educational interventions and adverse news about calcium-channel blockers on first-line prescribing of antihypertensive drugs to elderly people in British Columbia. Lancet 1998, 352:943-948.
18. Boltri JM, Gordon ER, Vogel RL: Effect of antihypertensive samples on physician prescribing patterns. Fam Med 2002, 34:729-731.